News
EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission ...
Androgen deprivation therapy is a lifesaving therapy used by thousands of men each year, but some patients are warning of ...
The European Commission has granted marketing authorization in the European Union (EU) for German pharma major Bayer’s Nubeqa ...
During a live event, Jahan Aghalar, MD, discussed the efficacy and safety of darolutamide plus ADT in mHSPC in the ARANOTE ...
EEST Darolutamide receives EU approval in third indication for patients with advanced prostate cancer European Commission granted approval ...
Berlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa ...
2d
MedPage Today on MSNFracture Risk Down With Osteoporosis Drug in Metastatic Prostate CancerWith regard to the choice of bone-protecting agent, denosumab (Xgeva) improved bone density and reduced fracture risk in a ...
Hormone therapy for metastatic prostate cancer comes in three main types: ADT, androgen synthesis inhibitors, and androgen receptor blockers.
European Union approves Bayer’s Nubeq for patients with advanced prostate cancer: Berlin Tuesday, July 22, 2025, 11:00 Hrs [IST] The European Commission has granted marketing au ...
Androgen deprivation therapy (ADT) has long been a foundation in the management of prostate cancer. Since the introduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results